title: Immunologic monitoring studies in advanced cancer patients treated with recombinant human gamma interferon (IFN-gamma 4A).
abstract: Thirty-nine patients with a variety of advanced malignancies were treated with recombinant IFN-gamma 4A (AMGen, specific activity 1 to 5 x 10(7) U/mg protein). IFN-gamma 4A was administered at a dose of 10-2,000 micrograms/m2/d. Following a 2-week rest, a maintenance phase was continued with injections 3 d/wk. Immunologic monitoring studies were performed on patients' peripheral blood cells before administration of IFN-gamma 4A, then on Days 15 and 90. Flow cytometric analysis was used to determine the absolute number of CD 3+, CD 4+, CD 8+, CD 19+, and CD 16+ cells using a panel of monoclonal antibodies. Natural killer (NK) cell function was assayed by monitoring lysis of the K562 cell line in the Cr51 release assay. Changes from baseline were observed on Days 15 and 90 in all parameters studied, although the ratio of helper to suppressor cells seemed to remain within the normal range. Whereas there were no substantial changes in CD 3+ and CD 4+ cells on Day 15, IFN-gamma 4A had an enhancing effect on CD 8+, CD 19+, and CD 16+ cells. This trend continued at Day 90 only for CD 19+ and CD 16+ cells at the higher dose levels. An increase in functional NK cell activity at Day 15 was less noted on Day 90. Comparison of intravenous (IV) to intramuscular-subcutaneous (IM-SC) administration showed differences in the effect on lymphocyte subpopulations at 450 and 1,000 micrograms. The effect of IFN-gamma 4A on the equilibrium among lymphocyte subpopulations and the possibility of its role in combination therapy with other biologic response modifiers are discussed.
authors.affiliation: Department of Pathology, Milton S. Hershey Medical Center, Pennsylvania State University, Hershey.
authors.forename: P J
authors.initials: PJ
authors.lastname: Romano
authors.forename: A
authors.initials: A
authors.lastname: Lipton
authors.forename: H A
authors.initials: HA
authors.lastname: Harvey
authors.forename: M J
authors.initials: MJ
authors.lastname: Bartholomew
authors.forename: G
authors.initials: G
authors.lastname: Giudice
authors.forename: F
authors.initials: F
authors.lastname: Kloszewski
authors.forename: L
authors.initials: L
authors.lastname: Witkowski
authors.forename: M R
authors.initials: MR
authors.lastname: Downing
mesh_terms: D015703:Antigens, CD / Q000276:immunology; D002857:Chromium / Q000493:pharmacokinetics; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007275:Injections, Intravenous; D007371:Interferon-gamma / Q000008:administration & dosage / Q000627:therapeutic use*; D007694:Killer Cells, Natural / Q000276:immunology; D008297:Male; D015166:Monitoring, Immunologic; D009369:Neoplasms / Q000188:drug therapy / Q000276:immunology*; D011994:Recombinant Proteins; D013601:T-Lymphocytes / Q000276:immunology
chemical_list: D015703:Antigens, CD; D011994:Recombinant Proteins; C056557:interferon gamma-4A; D002857:Chromium; D007371:Interferon-gamma